Navigation Links
Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences
Date:12/1/2011

nts an effective treatment for most ER+ MBC patients, however acquired drug resistance to aromatase inhibitors leads to disease progression requiring less effective, more toxic chemotherapies.(1)  Delaying resistance and disease progression represents a significant unmet need that could prolong survival while decreasing health care costs associated with chemotherapy and hospitalization.

Hodgkin's Lymphoma
Hodgkin's lymphoma (HL) is a cancer of lymph tissue found in the lymph nodes, spleen, liver, bone marrow, and other sites.  It is most common among people ages 15 - 35 and 50 - 70.  Although the cause is not known, past infection with the Epstein-Barr virus (EBV) is thought to contribute to some cases and patients with HIV infection are more at risk than the general population.  It is estimated that 8,830 people in the US will be diagnosed with and 1,300 will die of the disease in 2011, with the prognosis of patients with relapsed HL being particularly poor.  HDACi have shown promise in treating this disease.  Preclinical studies have identified at least three complementary mechanisms to explain how HDACi may be effective in the treatment of HL (Buglio, Blood 2008): induction of apoptosis, regulation of cytokines and chemokines and alterations of cancer/testis antigens (Jona et al., Exp Hematol. 2011).

About Entinostat
Syndax's lead product entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. Entinostat is differentiated from other members of the class through its unique selectivity profile, pharmacokinetic properties and safety profile. Entinostat has been studied in more than 600 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies.

Breast cancer anim
'/>"/>

SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
2. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
4. Pharmacyclics Reports Fiscal 2012 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 53rd American Society of Hematology Annual Meeting
5. Biogen-Idecs BG-12 Shines At the Top of the Charts in the Treatment of Relapsing-Remitting Multiple Sclerosis
6. Neurology Devices Market to 2017 - High Potential for Usage of Neurostimulation Devices in Multiple Neurological Disorders to Drive Market Growth
7. Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
8. DxTerity and Caliper Life Sciences Partner to Deliver NEAT® Multiplex Assays on Calipers LabChip® Dx Platform
9. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
10. S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis
11. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... NEWS, Va. , Aug. 3, 2015 /PRNewswire/ ... be joining Orthopaedic & Spine Center ... them to manage their chronic pain through psychological ... Robinson is a Fellowship-trained, certified medical psychologist ... pain medicine. His vast experience ranges from assessment ...
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  CytomX, a biopharmaceutical ... cancer, today announced the promotion of several members ... Ray , who previously served as vice president ... promoted to senior vice president of corporate development ... held positions as the vice president of business ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Reportlinker.com announces that a new market research ... Advances in Large Scale BioManufacturing and Scale-Up ... A Comprehensive Study of ... This new ASM study provides a clear view ...
Cached Medicine Technology:Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
(Date:8/4/2015)... ... August 04, 2015 , ... The Law Offices of ... device lawsuit claims dealing with Inferior Vena Cava Filters (“IVC Filters”). , As lead ... cases for Cook IVC Filter clients under In re Cook Medical, Inc., IVC Filters ...
(Date:8/4/2015)... ... August 04, 2015 , ... In ... filed against Johnson & Johnson report that a new location for pretrial proceedings ... regular news updates and cancer warning information at their website, the Talcum Powder ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 04, 2015 , ... Lightning Labels is pleased to announce ... will usher in a new standard of sticker and label-making for the company. ... its twin objectives of quality and quantity without compromising the signature lightning-fast speed ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... results have been impressive so far". , Mr Cauchois attributes the success ... French sales partner Dicma and the healthcare technology offered by Winscribe's platform. ...
Breaking Medicine News(10 mins):Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... appearance of a cold sore is,a sign that your ... emerge, according to John Sherman, ND, noted naturopathic,physician and ... 80% and 90% of the adult population have the ... Dr. Sherman, who,is the author of The Complete Botanical ...
... Patient safety incidents cost the federal Medicare ... preventable deaths during 2004 through 2006, according to ... Study. HealthGrades, analysis of 41 million Medicare patient ... had, on average, a 43 percent lower chance ...
... WALTHAM, Mass., April 7, 2008 Repligen,Corporation (Nasdaq: ... and,Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 9:00 a.m. EDT, to provide,an update on the ... Thomson/CCBN and can be accessed via,Repligen,s website at ...
... from China is no cause for alarm , , MONDAY, ... probable case of human-to-human transmission of bird flu in ... that there,s a genetic component to human-to-human transmission of ... "This suggests that there,s some genetic component to resistance ...
... ALB ) will hold its quarterly conference call to ... ET., This call is being webcast by Thomson/CCBN and ... in the Investor,Information section., To listen ... In # 800-591-6942 International Dial In ...
... April 7, 2008 American Media, Inc. (AMI),today ... corporate website certain,information currently required to be disclosed ... its amended Senior Secured Credit Agreement., The ... certain key magazine titles during the period April ...
Cached Medicine News:Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 3Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 4Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 2Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 3Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2
... This therapeutic system is ... patient in mind. As ... and ongoing therapy, SONOCUR ... and effective therapy. Plus, ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... only one of the most modern lithotripters available ... from being designed for the treatment of the ... the MODULITH SLX can also be employed for ... equally suitable for the treatment of gallstones or ...
... The MINILITH SL1 developed by STORZ MEDICAL ... extensive experience in the field of kidney ... the specific requirements to be met by ... as has been outlined above. The MINILITH ...
Medicine Products: